After yesterday's market close, the San Francisco-based biopharmaceutical company reported a net loss of 40 cents per share, narrower than the loss of 42 cents per share that analysts were expecting.
Revenue for the quarter was $39.37 million, beating Wall Street's estimates of $28.82 million.
For 2015, the company said its net loss widened to $81.2 million, or a loss of 61 cents per share, compared to a net loss of $53.9 million, or a loss of 42 cents per share, in 2014.
"Nektar begins 2016 with two new medicines launched by our partners in the past year and multiple late-stage drug candidates advancing in the clinic," CEO Howard W. Robin said in a statement.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D- on the stock.
This is driven by a number of negative factors, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, generally high debt management risk and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: NKTRNKTR data by YCharts